NCT03646747 is a NA clinical trial of MRI scan in Head and Neck Cancer, sponsored by Sally Falk.

Who is sponsoring NCT03646747?

NCT03646747 is sponsored by Sally Falk.

What drugs are being tested in NCT03646747?

Interventions in NCT03646747: MRI scan.

What condition does NCT03646747 study?

NCT03646747 studies Head and Neck Cancer.

Is NCT03646747 still recruiting?

NCT03646747 is currently status unknown. Last updated 24 August 2018.

Last reviewed 2018-08-24 · How we verify

NCT03646747

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxygen Enhanced MRI Measurement in Head and Neck Cancer: Validation and Efficacy of Response.

Status unknown NA Last updated 24 August 2018

What this trial tests

NA trial testing MRI scan in Head and Neck Cancer in 40 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Sally Falk
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	40
Start date	1 September 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021

Drugs / interventions tested

MRI scan

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Sally Falk

Who can join

18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective pilot study to investigate the potential clinical value of oxygen-enhanced magnetic resonance (OE-MRI) biomarkers in head and neck radiotherapy.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Perspectives on Hypoxia Signaling in Tumor Stroma.
Zhang Y, Coleman M, Brekken RA. · · 2021 · cited 28× · PMID 34202979 · DOI 10.3390/cancers13123070
Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies.
Dewhirst MW, Mowery YM, Mitchell JB, Cherukuri MK, et al · · 2019 · cited 28× · PMID 30614815 · DOI 10.1172/jci126044
Oxygen-Enhanced MRI Detects Incidence, Onset, and Heterogeneity of Radiation-Induced Hypoxia Modification in HPV-Associated Oropharyngeal Cancer.
Dubec MJ, Price J, Berks M, Gaffney J, et al · · 2024 · cited 6× · PMID 39142654 · DOI 10.1158/1078-0432.ccr-24-1170
Imaging hypoxia for head and neck cancer: current status, challenges, and prospects.
Huang W, Li N, Zhu S, Zhang Y, et al · · 2025 · PMID 40860130 · DOI 10.7150/thno.112781
Translation of dynamic contrast-enhanced imaging onto a magnetic resonance-guided linear accelerator in patients with head and neck cancer.
Dubec MJ, Berks M, Price J, McDaid L, et al · · 2025 · PMID 39802650 · DOI 10.1016/j.phro.2024.100689

Verify or expand the search:

Other trials of MRI scan

Trials testing the same drug.

NCT07384559 — Exploratory Study Investigating the Urinary Bladder During Intermittent Catheterization in Healthy and Spinal Cord Injur · NA · not yet recruiting
NCT04103372 — Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Sur · NA · recruiting
NCT06227182 — Magnetic Resonance Imaging and Ultrasound Comparison With Load Evaluation · recruiting
NCT06236048 — Energetics and Glutamate in Schizophrenia · recruiting
NCT06185478 — Prostate Diffusion Imaging With Distortion Correction · NA · suspended

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Sally Falk trials

Trials by the same sponsor.

NCT02068378 — Visual Feedback With Optical Sensing - A Feasibility Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03646747 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sally Falk
Last refreshed: 24 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03646747.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing